Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Long-term Potentiation01:35

Long-term Potentiation

Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient profiling in relapsing multiple sclerosis: insights from a real-world observational study into the unmet medical needs of patients on disease-modifying therapy.

Journal of neurology·2026
Same author

A simple plan: chemotherapy-sparing approaches to early-stage and regional seminoma and nonseminoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Determination of chlorinated paraffins and olefins in plastic consumer products of the Swiss market.

Chemosphere·2025
Same author

Estimates of Current Capacity for Diagnosing Alzheimer's Disease in Sweden and the Need to Expand Specialist Numbers.

The journal of prevention of Alzheimer's disease·2024
Same author

Fingerprinting of chlorinated paraffins and their transformation products in plastic consumer products.

Chemosphere·2023
Same author

Plasma and cerebrospinal fluid concentrations of neurofilament light protein correlate in patients with idiopathic normal pressure hydrocephalus.

Fluids and barriers of the CNS·2023

Related Experiment Video

Updated: Jul 6, 2026

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis
08:48

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis

Published on: January 29, 2016

[Adherence to neurologic treatment. Lessons from multiple sclerosis].

S Kern1, H Reichmann, T Ziemssen

  • 1Klinik und Poliklinik für Neurologie,Multiple Sklerose Zentrum, Carl Gustav Carus Universitätsklinik, Fetscherstrasse 74, 01307, Dresden. kern@neuro.med.tu-dresden.de

Der Nervenarzt
|March 13, 2008
PubMed
Summary

Patient nonadherence to medical treatments is a major healthcare issue, especially for chronic conditions. Addressing adherence requires multifaceted interventions involving patients, doctors, and nurses.

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

Published on: December 26, 2015

Related Experiment Videos

Last Updated: Jul 6, 2026

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis
08:48

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis

Published on: January 29, 2016

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

Published on: December 26, 2015

Area of Science:

  • Healthcare management
  • Patient adherence research
  • Chronic disease management

Context:

  • Increasing prevalence of chronic conditions and aging populations.
  • Shift in perspective from patient blame to systemic factors in nonadherence.
  • Nonadherence poses significant challenges in modern healthcare systems.

Purpose:

  • To analyze the central aspects and consequences of adherence problems in long-term therapy.
  • To summarize factors influencing treatment motivation in multiple sclerosis (MS) patients.
  • To discuss intervention strategies for patients, doctors, and nurses.

Summary:

  • Nonadherence is a complex issue influenced by various factors, not solely patient responsibility.
  • Specific focus on multiple sclerosis (MS) highlights neurological and motivational challenges.
  • Multilevel interventions are crucial for improving long-term treatment adherence.

Impact:

  • Provides a framework for understanding and addressing patient nonadherence.
  • Offers targeted strategies for healthcare professionals to improve patient outcomes.
  • Contributes to better management of chronic conditions through enhanced adherence.